These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23434008)

  • 1. Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients.
    Alexopoulos D; Xanthopoulou I; Siapika A; Tsoni E; Stavrou K; Theodoropoulos KC; Davlouros P
    Int J Cardiol; 2013 Sep; 168(1):629-30. PubMed ID: 23434008
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
    Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction.
    Perl L; Zemer-Wassercug N; Rechavia E; Vaduganathan M; Orvin K; Weissler-Snir A; Lerman-Shivek H; Kornowski R; Lev EI
    J Thromb Thrombolysis; 2015 Jan; 39(1):1-7. PubMed ID: 25085573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
    Lhermusier T; Voisin S; Murat G; Mejean S; Garcia C; Bataille V; Lipinski MJ; Carrié D; Sié P
    Int J Cardiol; 2014 Jul; 174(3):874-6. PubMed ID: 24820749
    [No Abstract]   [Full Text] [Related]  

  • 6. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
    Alexopoulos D; Xanthopoulou I; Davlouros P; Tsigkas G; Damelou A; Theodoropoulos KC; Gkizas V; Hahalis G
    J Thromb Haemost; 2013 Feb; 11(2):381-4. PubMed ID: 23216658
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
    Laine M; Gaubert M; Frère C; Peyrol M; Thuny F; Yvorra S; Chelini V; Bultez B; Luigi S; Mokrani Z; Bessereau J; Toesca R; Champenois A; Dignat-George F; Paganelli F; Bonello L
    Platelets; 2015; 26(6):570-2. PubMed ID: 25275609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
    Angiolillo DJ; Curzen N; Gurbel P; Vaitkus P; Lipkin F; Li W; Jakubowski JA; Zettler M; Effron MB; Trenk D
    J Am Coll Cardiol; 2014 Apr; 63(15):1500-9. PubMed ID: 24333493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.
    Deharo P; Bassez C; Bonnet G; Pankert M; Quilici J; Lambert M; Verdier V; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Int J Cardiol; 2013 Dec; 170(2):e21-2. PubMed ID: 24231059
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.
    Eisen A; Lerman-Shivek H; Perl L; Rechavia E; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Kazum S; Codner P; Kornowski R; Lev EI
    J Thromb Thrombolysis; 2015 Jul; 40(1):70-5. PubMed ID: 25481810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from ticagrelor to prasugrel: a warning.
    Parodi G; Bellandi B; Antoniucci D
    Int J Cardiol; 2014 Oct; 176(3):1089-90. PubMed ID: 25125013
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes.
    Bonello L; Laine M; Cluzel M; Frere C; Mancini J; Hasan A; Thuny F; Gaubert M; Guieu R; Dignat-George F; Michelet P; Paganelli F; Kerbaul F
    Am J Cardiol; 2015 Aug; 116(3):339-43. PubMed ID: 26037292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction.
    Perl L; Lerman-Shivek H; Rechavia E; Vaduganathan M; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Codner P; Bental T; Battler A; Kornowski R; Lev EI
    J Am Coll Cardiol; 2014 Feb; 63(6):513-7. PubMed ID: 24148715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report.
    Xanthopoulou I; Stavrou EF; Kassimis G; Goudas P; Alexopoulos D
    Platelets; 2013; 24(3):239-41. PubMed ID: 22646854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Parodi G; Bellandi B; Xanthopoulou I; Capranzano P; Capodanno D; Valenti R; Stavrou K; Migliorini A; Antoniucci D; Tamburino C; Alexopoulos D
    Circ Cardiovasc Interv; 2015 Jan; 8(1):. PubMed ID: 25552565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
    Beigel R; Fefer P; Rosenberg N; Novikov I; Elian D; Fink N; Segev A; Guetta V; Hod H; Matetzky S
    Am J Cardiol; 2013 Nov; 112(10):1551-6. PubMed ID: 23972349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
    Alexopoulos D; Bhatt DL; Hamm CW; Steg PG; Stone GW
    Am Heart J; 2015 Jul; 170(1):3-12. PubMed ID: 26093859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.